TP53 and B-cell chronic lymphocytic leukemia: In recent years, evidence has been provided that a longer progression‐free survival (PFS) can be achieved with ibrutinib than with CIT in previously untreated CLL10, 11, 12 and expert opinions recommended ibrutinib upfront, especially in older patients with CLL and in younger patients with TP53 disruption or less favorable unfavorable immunogenetic characteristics, that is, unmutated configuration of the variable portion of the immunoglobulin (IGHV) gene.13, 14, 15